Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of June 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate by reference a press release dated June 20, 2018 (Exhibit 99.1), which is the primary source of material information for this period.
Key Financial Metrics
The provided filing text does not contain specific financial data. It acts as a cover document referencing an external press release. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text.
Material Changes
The filing text does not detail specific material changes or comparative financial performance versus prior periods. It solely confirms the issuance of a press release on June 20, 2018, which must be reviewed to identify any material events or changes.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, and contingencies are not explicitly stated in the Form 6-K cover text. These details are contained within the attached Exhibit 99.1 (Press Release), which is incorporated by reference but not reproduced in the provided input.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 (Press Release dated June 20, 2018) to understand the specific material event triggering this filing.
- Confirm the registrant name is Galapagos NV, noting a discrepancy with the metadata field "Lakefront Biotherapeutics NV."
- Review the referenced Registration Statements (Forms F-3 and S-8) for updated prospectus information as noted in the incorporation clause.
- Check for any clinical trial updates or partnership announcements typically found in Galapagos NV press releases from this period.